AsalyxBio closes seed funding to advance core program in first-in-humclinical trials

The company’s PANTHER technology platform enables selective targeted delivery of therapeutic compounds directly to neutrophils and other immune cells

ANN ARBOR, Mich., Feb.23, 2021 / PRNewswire / – Asalyxa Bio, Inc., a biopharmaceutical company that develops nano-engineered, immune cell-targeted therapies, today announced the closure of an over-subscribed seed funding round for a total of over $ 2 million. The funding was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, Western Michigan University BRCC, Ann Arbor Spark, Woodward Angels, and other undisclosed investors. Income from the loan will be used to advance Asalyxa …

Read More On Original Publisher

This Content is Original Published by